|| Checking for direct PDF access through Ovid
to estimate the frequency of dyslipidaemia (DLP) and to determine the risks after heart transplantation (HTx).From 2010 to 2017 we performed 96 HTx (mean age 46,5±13,9 yrs; n=5 – children, 15 [10;16] yrs old). All patients were divided into 2 groups according to causes of heart failure: ischemic heart disease (IHD) (50%, n=48) and others (50%, n=48). Before HTx 36,5% (n=35) of recipients had the level of cholesterol > 4,5 mmol/l. Before HTx 56% (n=27) of IHD recipients underwent CABG or stent-implantation. Before HTx coronary angiography (CAG) was performed in donors older than 40 yrs (51%, n=49). All recipients were treated with triple-drug therapy (steroids, calcineurin inhibitors, mycophenolic acid/everolimus), induction (basiliximab – 79%, thymoglobulin – 21%) and also by statins to treat or to prevent DLP. We estimated the results of lipid profile and frequency of DLP.In 6 months after HT the level of total cholesterol (TC) did not change in patients with IHD (4,5±1,2 and 4,9±1,1 mmol/l, p>0,05). However, it increased in recipients without IHD history (3,9±1,2 and 4,5±0,9 mmol/l, p<0,05). Despite of therapy by statins DLP took place in all children recipients. After HTx 11 patients continued smoking and had higher level of TC (6,1±2,1 mmol/l, p>0,05). Patients who treated with everolimus had worse DLP than those with mycophenolic acid (TC - 5,9±0,9 vs. 4,5±1,6 mmol/l, p<0,05; LDL – 3,4±1,2 vs. 2,1±1,0 mmol/l, p>0,05; triglycerides – 2,6±1,1 vs. 1,7±0,9 mmol/l, p>0,05). We found correlations between TC in non-IHD recipients and time in ICU (r=0,549; p<0,001), time spent on inotropes (r=0,539; p<0,001) and the age of donors (r=0,400; p<0,05).DLP may occur in all heart transplanted patients, especially non-IHD ones need to take under control.